Ronald W. Irwin, Ph.D.
Affiliations: | Molecular Pharmacology and Toxicology | University of Southern California, Los Angeles, CA, United States |
Google:
"Ronald Irwin"Mean distance: 10867.7
Parents
Sign in to add mentor| Roberta Diaz Brinton | grad student | 2002-2008 | USC | |
| (Estradiol regulation of cerebral metabolism: Implications for neuroprotection and mitochondrial bioenergetics.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wang JY, Trivedi AM, Carrillo NR, et al. (2017) Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics |
| Irwin RW, Hernandez G, Solinsky CM, et al. (2017) [P4-020]: CLINICAL TRIAL RECRUITMENT FRAMEWORK FOR EARLY ALZHEIMER's DISEASE Alzheimer's & Dementia. 13: P1262-P1262 |
| Irwin RW, Solinsky CM, Rodgers KE, et al. (2016) P1-072: Comparative Pharmacokinetic Assessment of Allopregnanolone to Develop a Regenerative Therapeutic for Mild Cognitive Impairment and Early Alzheimer’s Disease Alzheimer's & Dementia. 12: P430-P430 |
| Brinton RD, Swanson HM, Irwin RW. (2016) P4-026: Allopregnanolone Promotes Cholesterol and Amyloid-Beta Clearance Mechanisms: Assessment of a Regenerative Therapeutic for Alzheimer’s Disease Alzheimer's & Dementia. 12: P1024-P1025 |
| Irwin RW, Solinsky CM, Loya CM, et al. (2015) Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease. Plos One. 10: e0128313 |
| Irwin RW, Kim K, Green CE, et al. (2015) P1-303: Allopregnanolone chronic exposure using regenerative treatment regimen: Preclinical ind enabling toxicology indicating safety Alzheimer's & Dementia. 11: P472-P473 |
| Irwin RW, Solinsky CM, Brinton RD. (2014) Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders. Frontiers in Cellular Neuroscience. 8: 203 |
| Irwin RW, Brinton RD. (2014) Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise. Progress in Neurobiology. 113: 40-55 |
| Irwin R, Chen S, To J, et al. (2013) P4-016: Allopregnanolone as a regenerative therapeutic for Alzheimer's disease, 2: Bridging subcutaneous to intravenous formulations for clinical trials Alzheimer's & Dementia. 9: P710-P711 |
| Yao J, Chen S, Wong K, et al. (2013) P4-013: Allopregnanolone as a regenerative therapeutic for Alzheimer's disease, 3: Evidence for potentiation of brain mitochondrial function Alzheimer's & Dementia. 9: P709-P710 |